Healthcare Infrastructure, Operations & Supply ChainOS Therapies Gets Patent Allowance for OST-HER2 ManufacturingBusiness WireFebruary 20, 2025August 1, 2025 by Business WireFebruary 20, 2025August 1, 20250201 Patent Term Adjustment will provide market exclusivity in the United States into 2040 for all therapeutic indications OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology...
